Year All20232022202120202019201820172016201520142013201220112009 Feb 08, 2023 REGENXBIO Announces Presentation at the Virtual SVB Securities Global Biopharma Conference Feb 06, 2023 REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference Jan 23, 2023 REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients Jan 09, 2023 REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONS Jan 03, 2023 REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Feb 08, 2023 REGENXBIO Announces Presentation at the Virtual SVB Securities Global Biopharma Conference
Feb 06, 2023 REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference
Jan 23, 2023 REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients
